A Strategy to Treat COVID‐19 Disease With Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Preclinical Pharmacokinetic Study

• Egile Nagusiak: Tien‐Tzu Tai (Egilea), Tzung‐Ju Wu (Egilea), Huey‐Dong Wu (Egilea), Yi‐Chen Tsai (Egilea), Hui‐Ting Wang (Egilea), An‐Min Wang (Egilea), Sheue‐Fang Shih (Egilea), Yee‐Chun Chen (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2021-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a newly identified pathogen causing the coronavirus disease 2019 (COVID‐19) pandemic. Hydroxychloroquine (HCQ), an antimalarial and anti‐inflammatory drug, has been shown to inhibit SARS‐CoV‐2 infection in vitro and tested in clinical s...